News Faron’s Clever-1 drug shows promise in blood cancers Faron Pharmaceuticals has reported data from a phase 1/2 trial pointing to the potential of its macrophage-directed antibody bexmarilimab as a treatment for blood cancers
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face